AmacaThera's new non-opioid pain relief drug shows promise after successful early trials.

AmacaThera has reported successful Phase 1 clinical trial results for AMT-143, a non-opioid anesthetic that offers up to 14 days of sustained pain relief. This innovation aims to reduce reliance on opioids, addressing the opioid crisis and providing safer post-surgery pain management. The promising data has attracted investor interest, and AmacaThera is planning for Phase 2 trials while seeking partnerships to expedite market entry.

November 20, 2024
3 Articles